
View all data FOR FREE!
Create an account today, no credit card required.
Issue Type | XXXX |
---|---|
Country | United States |
Industry | XXXX |
Region | XXXX |
Maturity Date | 2043-08-15 |
Par Value | 2000 |
Callable | XXXX |
Next Call Date | XXXX |
Call Type | XXXX |
Call Price (%) | XXXX |
Series | XXXX |
Class | XXXX |
Maturity Structure | XXXX |
Amount Outstanding (mil) | 4.06 |
Coupon | 5.25 |
---|---|
Coupon Type | XXXX |
Coupon Frequency | XXXX |
First Coupon Date | XXXX |
Last Coupon Date | XXXX |
Sinking Fund | XXXX |
---|---|
Security | XXXX |
Subordination | XXXX |
Debt Type | XXXX |
Issue Date | XXXX |
---|---|
Dated Date | XXXX |
Issue Size (mil) | 400 |
Min. Piece | XXXX |
Min. Increment | XXXX |
This Celgene Corp. corporate note has a 5.25% fixed rate coupon paid on a semi-annual basis. It was issued on August 06, 2013 with an issue size of 400.00 million USD and matures on August 15, 2043 with a last coupon date of February 15, 2043. |
Celgene Corp., founded in 1986 and headquartered in Summit, New Jersey, is a biopharmaceutical company dedicated to developing innovative therapies for cancer and inflammatory disorders. The company's prominent products include Revlimid, a treatment for multiple myeloma, and Pomalyst, used for relapsed or refractory multiple myeloma, which have positioned Celgene as a leader in the biotechnology sector.